Form 4: Labcorp Director Kliphouse Receives 773 Restricted Stock Units

Labcorp Holdings Inc. director Kirsten M. Kliphouse was granted 773 restricted stock units, vesting fully on February 10, 2027.

Summary

• Kirsten M. Kliphouse, a director of Labcorp Holdings Inc. (LH), acquired 773 Restricted Stock Units (RSUs).
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The RSUs were granted on February 10, 2026, and are scheduled to vest fully on February 10, 2027.
• Following this transaction, Kliphouse beneficially owns an aggregate of 1,670 Restricted Stock Units.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event, reflecting ongoing director compensation and alignment with shareholder interests, without indicating any significant operational or financial changes.

Positives

• The grant of 773 Restricted Stock Units aligns the director's interests with long-term shareholder value.
• The transaction indicates continued commitment of a director to the company's future performance.

Negatives

• No specific negatives are identified in this routine compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

No specific future outlook or guidance is provided in this filing, which details an insider transaction.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to directors is a common practice in the healthcare diagnostics and laboratory services industry, aligning executive and director incentives with long-term company performance, similar to practices at peers like Quest Diagnostics or Eurofins Scientific.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a standard compensation practice across publicly traded companies, including those in the healthcare sector.
• Companies like Quest Diagnostics (DGX) and Charles River Laboratories (CRL) also utilize RSU grants as a component of their non-employee director compensation programs to foster long-term alignment with shareholder interests.
• The specific number of units granted (773) is relative to the company's stock price and the overall compensation philosophy, which varies by company size and industry benchmarks.

Related Party Transactions

• The grant of Restricted Stock Units to a director is a transaction between the company and a related party (director) as part of standard compensation practices.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially encouraging long-term value creation.
• Employees: No direct impact on general employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The 773 Restricted Stock Units are scheduled to vest fully on February 10, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine grant of Restricted Stock Units to a director as part of their compensation. Such a transaction is not typically a significant market moving event on its own and does not provide new fundamental information to warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Labcorp Holdings Inc., LH, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, SEC Form 4, Kirsten M. Kliphouse, Equity Grant